A new study presented at the ADA’s 85th Scientific Sessions links genetic predisposition for macronutrient preference with childhood intake of sugary drinks and fast food.
A large 68-week clinical trial found that a once-weekly combination injection of cagrilintide and semaglutide led to significant and sustained weight loss in adults with overweight or obesity, with over half achieving at least 20% weight reduction.
A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.
Once-weekly cagrilintide–semaglutide significantly reduced weight and improved glycemic control in adults with type 2 diabetes in the REDEFINE 2 trial.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Attendees of the Optometry’s Meeting 2025 lecture “Life-Threatening Eye Signs & Symptoms That Can’t Be Missed” learned, in part, about the 5 red flags of asymmetric lid ptosis that portend fatal conditions.
A new stem cell–derived islet therapy showed insulin independence, restored beta-cell function, and prevented severe hypoglycemia in type 1 diabetes, based on interim results presented at the ADA’s 85th Scientific Sessions.
The AOA Innovation Hub, which made its debut at Optometry’s Meeting 2025, was created to enable industry representatives and startup companies to share their innovations with meeting attendees.